Session: 250. Pediatric Bacterial Infections: From A to Z Saturday, October 7, 2017: 12:30 PM Background. KPC-CRE are multidrug-resistant organisms (MDRO) associated with morbidity and mortality worldwide. KPC-CRE infection prevalence is increasing in the pediatric population; however, multi-centered pediatric data are lacking. We sought to identify factors for KPC-CRE infections in children and to classify genotypes of infecting strains.
Background. Persons with cystic fibrosis (CF) are at increased risk for nontuberculous mycobacteria (NTM) lung infections, with a national annual prevalence of 13%. However, for CF patients in Hawaii, estimates are as high as 50%. Active duty military who have dependents with CF may be transferred to Hawaii as part of their service, potentially placing their dependent at increased risk for NTM. To better describe the epidemiology of NTM in a high-risk environment, we report prevalence and risk factors for CF patients living in Hawaii and seeking care at Tripler Army Medical Center (TAMC), the only CF center in Hawaii.
Methods. Data were extracted on CF patients treated at TAMC from 2010 to 2014, including sex, age, time residing in Hawaii, and culture results. NTM cases (≥ 1 positive culture) and non-cases (no positive cultures) were identified and prevalence estimated. Log-binomial regression was used to estimate adjusted relative risks (aRR) and 95% confidence intervals (CI) for risk factors.
Results. Of 43 CF patients, 17 (40%) had NTM isolated at least once; 11 (26%) had ≥2 positives. Annual prevalence averaged 30%. Overall, 13 (76%) cases had Mycobacterium abscessus, 5 (29%) M. avium complex (MAC), and 6 (35%) other rapid growers isolated; 9 (53%) had multiple species isolated. Mean time to first positive culture was 1.6 yrs (range: 0-7.1); only 2(11%) cases were positive at first culture. NTM cases were more frequently female (59%; P = 0.02) and older than non-cases (14.4 vs. 11.9 yrs; P < 0.0001). Among CF patients living in Hawaii for >6 years, 80% had NTM compared with only 19% of those in Hawaii for <3 years (P < 0.05) (Figure 1 ). After adjusting for sex and age, each additional year in Hawaii increased the risk for NTM by over two-fold (aRR=2.5, 95% CI=1.2-5.6; P = 0.02), especially for M. abscessusand other rapid growers (aRR=2.4, 95% CI=1.0-5.8; P = 0.04).
Conclusion. Prevalence of NTM in CF patients in Hawaii is two-fold greater than the national average, with each additional year of residence more than doubling the risk of infection. Further, nearly 80% of patients had M. abscessus, which is harder to treat and is associated with more severe clinical outcomes. Persons affected by CF should be aware of the increased risk of NTM associated with residence in Hawaii.
This work was supported in part by the DIR, NIAID, NIH and by TAMC. Background. The Tijuana, Mexico and San Diego, California, is the world's most transited frontier. We have previously published pneumococcal serotype replacement following PCV-7 introduction, especially by serotypes 19-A, 3 and 6A/C. Since May/2012 universal vaccination with PCV-13 was introduced for all children. This study analyzes the effectiveness of PCV-13 after its implementation in the region.
Methods. Since October/2005 until March/2017 (11.5 years) we underwent an active surveillance for all Invasive Pneumococcal Diseases (IPD) in children < 16 years admitted at the Tijuana General Hospital. Only culture-confirmed cases were included. Following identification, serotyping was performed using the Quellung Reaction (Statens Serum Institute ® Copenhagen, Denmark). Descriptive analysis was performed using Excel ® . Results. Fifty-seven cases of confirmed IPD were found. Clinical diagnosis were pleural empyemas (PPE) (45.6%), meningitis (PM) (28%), otomastoiditis (15.7%), only sepsis (7%), and bacteremic pneumonia (3.5%). Median age was of 3.9 years (2 days -15.9 years), median hospitalization days was of 14 (1-90). Overall mortality was of 6 (10.5%). Following PCV13 introduction there was a decreased on overall IPD mortality by 73.29%, overall IPD by 68%, PPE by 68.1%, and PM by 55.4%. However, during 2015-16, we had three PM cases, two of which were immunocompromised patients, and none vaccinated with PCV13. From an average of 1.75 yearly cases due to pneumococcal serotype 19-A before PCV13 implementation, there had been no patients with IPD's caused by this serotype. (See Figure 1) . After PCV13 vaccination, serotypes associated with IPD cases had been as follow: Two 22F, and one each by 6A, 18C, 3, 7F, 15, 7B, 35B, 24F and 33F.
Conclusion. This is the first Mexican study based on active surveillance that shows consistent effectiveness of PCV-13 on reduction of overall IPD, disappearance of pneumococcal serotype 19-A, and strong impact on PPE in children. Effectiveness on PM is still above 50%, however, during 2015-16 there had been three cases, but with particular conditions (immunodeficiencies and no vaccination). Continuous active surveillance is mandatory.
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